Issues
-
Cover Image
Cover Image
Visualization of chromatin disassembly ongoing in tumor cell treated with an anticancer drug candidate curaxin CBL0137. Binding of CBL0137, as well as some other small molecules, to cellular DNA alters DNA helical structure, leading to nucleosome disassembly and loss of histones from chromatin. This is manifested as a shift from sharp to diffuse distribution of H1 histone tagged with mCherry fluorescent protein from the right to the left panel in the top row. This process is dependent on whether small molecules cause or do not cause DNA damage. Histone chaperone FACT binds destabilized nucleosomes in which a shift of the green fluorescence is seen that corresponds with FACT subunit SSRP1 tagged with a green fluorescent protein from the nucleoplasm and the nucleoli to chromatin (middle row, right to left panels). The ability to cause “chromatin damage” correlates better with anticancer potency of small molecules than their DNA damage capability, suggesting that it plays an important role in the anticancer activity of DNA binding small molecules. Bottom, a superposition of images in the two top rows. For details, see article by Nesher and colleagues on page 1431. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Perspectives
Genome and Epigenome
Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis
Metabolism and Chemical Biology
Molecular Cell Biology
Breast Cancer Targeting through Inhibition of the Endoplasmic Reticulum-Based Apoptosis Regulator Nrh/BCL2L10
E6 Protein Expressed by High-Risk HPV Activates Super-Enhancers of the EGFR and c-MET Oncogenes by Destabilizing the Histone Demethylase KDM5C
Tumor Biology and Immunology
CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1–Mediated ERK and BCL2/Cyclin D1 Pathways
Translational Science
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF
A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo
Convergence and Technologies
Improved Evaluation of Antivascular Cancer Therapy Using Constrained Tracer-Kinetic Modeling for Multiagent Dynamic Contrast-Enhanced MRI
Letters to the Editor
Correction
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.